Recently, online rumors claiming ‘widespread resistance to oseltamivir’ have sparked public concern about the effectiveness of this common flu treatment. Medical experts have clearly debunked these claims, stating that oseltamivir remains highly effective against the vast majority of circulating influenza strains, and the notion of ‘widespread resistance’ lacks scientific evidence.Oseltamivir is a neuraminidase inhibitor primarily used to treat and prevent influenza A and B. The World Health Organization (WHO) and national disease control agencies continuously monitor antiviral resistance in influenza viruses. Surveillance data show that while isolated cases of resistance have been reported in certain regions, the overall global resistance rate to oseltamivir remains extremely low—far below the threshold that would compromise its clinical utility.Experts stress that appropriate use of antiviral medications is crucial to preventing resistance. Patients should use oseltamivir only under medical supervision and avoid stockpiling or misusing the drug. Moreover, annual influenza vaccination remains the most effective way to prevent flu. The public is advised not to panic over misinformation but to rely on authoritative health sources for accurate guidance during flu season.
近期，网络上流传‘奥司他韦出现广泛耐药’的说法，引发公众对流感治疗药物有效性的担忧。对此，多位医学专家明确辟谣：目前奥司他韦在临床上仍对绝大多数流感病毒株保持良好疗效，所谓‘普遍耐药’的说法缺乏科学依据。奥司他韦（Oseltamivir）是一种神经氨酸酶抑制剂，主要用于治疗和预防甲型、乙型流感。世界卫生组织（WHO）及各国疾控机构持续监测流感病毒的耐药情况。数据显示，尽管个别地区曾报告过零星耐药病例，但全球范围内奥司他韦的总体耐药率极低，远未达到影响临床使用的程度。专家强调，合理使用抗病毒药物是防止耐药发生的关键。患者应在医生指导下规范用药，避免自行囤药或滥用。此外，接种流感疫苗仍是预防流感最有效的手段。公众无需因个别谣言恐慌，而应关注权威渠道发布的健康信息，科学应对流感季节。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/641.html